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As increased angiogenesis has been linked with the progression of ovarian cancer, a number of anti-angiogenic
agents have been investigated, or are currently in development, as potential treatment options for patients with
advanced disease. Bevacizumab, a recombinant monoclonal antibody against vascular endothelial growth factor,
has gained European Medicines Agency approval for the front-line treatment of advanced epithelial ovarian cancer,
fallopian tube cancer or primary peritoneal cancer in combination with carboplatin and paclitaxel, and for the
treatment of first recurrence of platinum-sensitive ovarian cancer in combination with carboplatin and gemcitabine.
We conducted a systematic literature review to identify available efficacy and safety data for bevacizumab in ovarian
cancer as well as for newer anti-angiogenic agents in development. We analyzed published data from randomized,
controlled phase II/III clinical trials enrolling women with ovarian cancer to receive treatment with bevacizumab. We
also reviewed available data for emerging anti-angiogenic agents currently in phase II/III development, including
trebananib, aflibercept, nintedanib, cediranib, imatinib, pazopanib, sorafenib and sunitinib. Significant efficacy gains
were achieved with the addition of bevacizumab to standard chemotherapy in four randomized, double-blind,
phase III trials, both as front-line treatment (GOG-0218 and ICON7) and in patients with recurrent disease (OCEANS
and AURELIA). The type and frequency of bevacizumab-related adverse events was as expected in these studies
based on published data. Promising efficacy data have been published for a number of emerging anti-angiogenic
agents in phase III development for advanced ovarian cancer. Further research is needed to identify predictive or
prognostic markers of response to bevacizumab in order to optimize patient selection and treatment benefit. Data
from phase III trials of newer anti-angiogenic agents in ovarian cancer are awaited.
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therapiesIntroduction
Ovarian cancer is the seventh most common cancer in
women [1], with an estimated 225,500 new cases and
140,200 deaths globally in 2008 [2]. Symptoms of the
disease are non-specific, including abdominal discomfort
or fullness, dyspepsia, and bloating, which may mimic
other conditions and lead to a delay in diagnosis [1].
Consequently, 75% of women are diagnosed with ad-
vanced disease (International Federation of Gynecology
and Obstetrics [FIGO] stage III or IV) [3], which has a* Correspondence: garavantinos@yahoo.gr
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article, unless otherwise stated.median overall survival (OS) of 15–23 months and an
estimated 5-year survival of just 20% [4]. Around 90% of
all ovarian cancers are epithelial ovarian cancers (EOCs)
and are believed to arise from the ovarian surface epithe-
lium or mullerian derivatives, including the fallopian
tube; primary ovarian cancers also include ovarian-type
peritoneal tumors [4].Current treatment options
Surgery is effective in most cases of early stage ovarian can-
cer (FIGO stage I-IIA) with a 5-year survival rate of around
90% [5]. Adjuvant chemotherapy for well-staged early stage
ovarian cancer is controversial [4] but some studies have
shown a benefit [6]. Clinical practice guidelines developedioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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as adjuvant treatment in patients with intermediate and
high-risk early stage ovarian cancer [4].
After surgical cytoreduction, the treatment of choice
for patients with advanced EOC (FIGO stage IIB-IIIC) is
platinum-based chemotherapy (six cycles of carboplatin
plus paclitaxel [CP] given every 3 weeks) [4]. Recently a
modified CP regimen with weekly paclitaxel resulted in
better long-term outcome than the 3-weekly regimen in
a phase III study in Japanese women with advanced
ovarian cancer [7,8], with confirmatory findings reported
in European women in the randomized, multicenter
phase III MITO-7 study [9], and in the chemotherapy
arm of the phase III GOG-0262 trial [10]. This regimen
has now been included in the NCCN treatment guidelines
[11]. Although approximately 80% of patients respond to
front-line chemotherapy, more than 70% of patients with
advanced stage disease recur within 5 years and develop
drug resistance [12,13].
For recurrent disease, the treatment choice is based on
the timing and nature of the recurrence and the extent
of prior chemotherapy [4]. Platinum-sensitive patients with
a treatment-free interval > 24 months and good perform-
ance status should be considered for surgical resec-
tion [4]. Patients responding to front-line platinum-
containing chemotherapy are very likely to respond to
a rechallenge with platinum-based therapies. However,
patients relapsing after front-line platinum-paclitaxel
chemotherapy are at risk of significant neurotoxicity
if retreated within 12 months with the same regimen.
Rechallenge with platinum-based therapies in patients
with platinum-refractory disease yields a response rate
of only 10%. Similarly low response rates have also been
reported with a number of agents in platinum-paclitaxel-
refractory disease [4]. More effective treatment strategies,
particularly molecular targeted agents, are required to
improve outcomes for women with advanced ovarian
cancer.
Angiogenesis and ovarian cancer
The vascular endothelial growth factor (VEGF) family
consists of VEGF-A (often referred to as VEGF), VEGF-B,
VEGF-C, VEGF-D, placental growth factor (PlGF), VEGF-E
and VEGF-F [14]. VEGF-mediated angiogenesis plays a
vital role in normal ovarian function, controlling the cyc-
lical growth of ovarian follicles and the development and
maintenance of the corpus luteum [14,15]. However, there
is a well-established association between VEGF overex-
pression, increased angiogenesis and the development and
progression of ovarian cancer. In a literature review of
nine studies including 529 patients with newly diagnosed
ovarian cancer, high serum VEGF levels correlated with
higher risk of death or recurrence [16]. Five of the studies
found serum VEGF to be an independent prognosticfactor for OS in multivariate analyses. In at least one of
the studies, a statistically significant association was iden-
tified between serum VEGF and FIGO stage, tumor grade
and size, lymph node involvement and presence of ascites.
VEGF has also been implicated in the peritoneal dissemin-
ation of ovarian cancer and the development of malignant
ascites [17] which is inversely linked with survival [14,18].
Given the association between increased angiogenesis
and the progression of ovarian cancer, a number of anti-
angiogenic agents are currently in development as poten-
tial treatment options for patients with advanced disease.
Bevacizumab is a recombinant, humanized, monoclonal
antibody that binds to all isoforms of VEGF [19]. Bevaci-
zumab is indicated for the treatment of several solid
tumors in combination with cytotoxic chemotherapy,
including non-small cell lung cancer, metastatic colo-
rectal cancer, metastatic renal cell carcinoma, metastatic
breast cancer (EU only) and glioblastoma. Bevacizumab
has gained European Medicines Agency approval, in com-
bination with CP, for the front-line treatment of pa-
tients with advanced EOC, fallopian tube cancer (FTC)
or primary peritoneal cancer (PPC), and, in combin-
ation with carboplatin and gemcitabine (CG), for the
treatment of first recurrence of platinum-sensitive ovarian
cancer.
The purpose of this systematic review was to summarize
available efficacy and safety data for bevacizumab in ovarian
cancer and to highlight data for emerging anti-angiogenic
agents in phase II/III development.
Search strategy
We designed a systematic literature review to identify
published randomized, controlled, prospective phase
II/III clinical trials of bevacizumab in women aged ≥
18 years with histologically proven EOC, FTC or PPC
and no concurrent malignancies. We also searched for
studies of promising new anti-angiogenic agents in ovar-
ian cancer.
PubMed/Medline and Embase databases were searched
from 1 January 2002 to 8 November 2013, using the terms:
AEE788; aflibercept; AMG 386; angiogenesis inhibitors;
anti-VEGF; bevacizumab; BIBF 1120; cediranib; imatinib;
nintedanib; pazopanib; perifosine; sorafenib; sunitinib;
trebananib; vascular endothelial growth factor; VEGF-
receptor AND ovarian cancer OR fallopian tube cancer
OR primary peritoneal cancer. Congress abstracts from
ASCO, ECCO-ESMO and SGO were also searched for
these agents from 1 January 2009 to 8 November 2013.
Results were limited to peer-reviewed, English language
articles only. Reviews, meta-analyses, case reports, edito-
rials, and letters were excluded.
From a total of 176 articles and 204 abstracts identi-
fied in the search, 57 articles and 98 abstracts met the
criteria for inclusion.
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Phase II trial data
One randomized phase II trial of bevacizumab was identi-
fied. The STAT study is examining the efficacy of front-
line bevacizumab plus erlotinib consolidation therapy
following CP plus bevacizumab induction therapy in
patients with EOC, FTC or PPC [20]. Of 60 enrolled pa-
tients, 12 were taken off study prior to randomization,
leaving 23 patients in the bevacizumab group and 25 pa-
tients in the bevacizumab plus erlotinib group. Overall, 6
patients achieved a complete response, 26 had a partial re-
sponse, and 20 had stable disease. Progression-free sur-
vival (PFS) data from the study are not yet mature.
Phase III trial data
Efficacy data are available from four randomized, double-
blind, phase III trials of bevacizumab in advanced ovarian
cancer: GOG-0218 [21] and ICON7 [22,23] in the front-
line treatment setting and OCEANS [24,25] and AURELIA
[26,27] in patients with recurrent disease (Table 1).
GOG-0218
The GOG-0218 study enrolled 1,873 women with newly
diagnosed stage III (incompletely resectable) or stage IV
EOC to receive: CP with placebo (n = 625); CP with bev-
acizumab from cycles 2–6 and placebo from cycles 7–22
(bevacizumab initiation, n = 625); or CP with bevacizu-
mab (bevacizumab throughout, n = 623) (Figure 1A). At
the time of the primary analysis, 76.3% of patients were
alive with a median follow-up of 17.4 months [21]. Com-
pared with the control arm, the primary endpoint of PFS
was longer in the bevacizumab initiation arm (hazard ra-
tio [HR] 0.908; p = 0.16; median 11.2 vs. 10.3 months)
and significantly longer in the bevacizumab throughoutTable 1 Summary of efficacy data from randomized, controlled
Study (n) Regimen ORR (C
[p
GOG-0218 [21] CP + placebo vs. CP + Bev vs.
CP + Bev→ Bev maintenance
(n = 1,873)
ICON7 [22,23] CP vs. CP + Bev→ Bev maintenance 48
(n = 1,528) [<
OCEANS [24,25] CG + placebo vs. CG + Bev 57.4
(n = 484) [<
AURELIA [26,27] CTx (PLD, P or Top) vs. CTx + Bev 12.6
(n = 361) [
Bev = bevacizumab. C = carboplatin. CR = complete response. CTx = chemotherapy.
survival. P = paclitaxel. PFS = progression-free survival. PLD = pegylated liposomal do
aCP + Bev vs. CP + placebo.
bCP + Bev→ Bev vs. CP + placebo.
cInterim data.arm (HR 0.717; p < 0.001; median 14.1 vs. 10.3 months)
(Table 1). The maximum separation of the survival curves
for the control group and the bevacizumab throughout
group occurred at 15 months, with convergence around
9 months later (Figure 1B). A pre-specified CA-125 cen-
sored analysis (progression events based only on CA-125
criteria were not counted as events) showed a median PFS
of 12.0 months in the control group and 18.0 months in
the bevacizumab throughout group (HR 0.645; p < 0.001)
[21]. An Independent Review Committee (IRC) confirmed
these findings, reporting a median PFS of 13.1 months in
the control arm versus 19.1 months in the bevacizumab
throughout arm (HR 0.630; p < 0.0001) [28]. A consistent
treatment effect was observed across patient subgroups
stratified by age, performance status, tumor grade, histo-
logic type and cancer stage [21]. OS, however, was not sig-
nificantly different between the bevacizumab-containing
treatment arms and the control arm (Table 1). Quality of
life (QoL), assessed in 1,693 eligible patients using the
Trial Outcome Index (TOI) of the Functional Assessment
of Cancer Therapy-Ovary (FACT-O) questionnaire, im-
proved from baseline to cycle 13 in all treatment groups.
Patients receiving bevacizumab had lower mean FACT-O
TOI scores during chemotherapy than patients in the con-
trol group (2.7 points and 3.0 points lower for the initi-
ation and throughout groups, respectively; p < 0.001 in
both cases), but no significant between-group differences
were observed after the completion of chemotherapy [21].
ICON7
In the ICON7 study, 1,528 women with high-risk early
stage ovarian cancer (9% of the study population) or ad-
vanced EOC, FTC or PPC were randomized to receive
front-line CP (n = 753) or CP plus bevacizumab followedphase III trials of bevacizumab in advanced ovarian cancer
R + PR), % Median PFS, months Median OS, months
value] [HR; p value] [HR; p value]
–
10.3 vs. 11.2 vs. 14.1 39.3 vs. 38.7 vs. 39.7
[0.908; 0.16]a [1.036; 0.76]a
[0.717; < 0.001]b [0.915; 0.45]b
vs. 67 17.4 vs. 19.8 Restricted mean
survival time, months
0.001] [0.87; 0.04] 44.6 vs. 44.5
vs. 78.5 8.4 vs. 12.4 33.7c vs. 33.4c
0.0001] [0.484; < 0.0001] [0.960; 0.736]
vs. 30.9 3.4 vs. 6.7 13.3 vs. 16.6
0.001] [0.48; < 0.001] [0.85; 0.174]
G = gemcitabine. HR = hazard ratio. ORR = overall response rate. OS = overall
xorubicin. PR = partial response. Top = topotecan.
Figure 1 GOG-0218 randomized, double-blind, placebo-controlled phase III trial: (A) study design; (B) progression-free survival analysis
(reproduced with permission) [21]. EOC = epithelial ovarian cancer. PPC = primary peritoneal cancer. FTC = fallopian tube cancer. C = Carboplatin.
AUC = area under the curve. P = Paclitaxel. GOG = Gynecologic Oncology Group. Bev = bevacizumab. q3w = once every 3 weeks.
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(Figure 2A). Median follow-up was 19.4 months with
759 progression or death events. A statistically signifi-
cant increase in PFS, the primary endpoint, was noted in
the bevacizumab arm relative to the CP arm (HR 0.81,
95% confidence interval [CI]: 0.70–0.94; p = 0.004; me-
dian 19.0 vs. 17.3 months) [22]. Similar results were ob-
tained in an updated analysis of PFS and OS data after a
median follow-up of 28 months with 934 progression ordeath events reported (Table 1). The effect of bevacizumab
changed over time, with maximal benefit at 12 months,
which diminished by 24 months post-randomization
(Figure 2B). A significantly higher objective response
rate (ORR) was observed with bevacizumab plus CP
versus CP alone (p < 0.001) (Table 1). Final OS results
from the trial, after a median follow-up of 49 months,
were reported as a restricted mean survival time im-
provement of 0.9 months from 44.6 months with CP
Figure 2 ICON7 randomized, double-blind, placebo-controlled phase III trial: (A) study design (B) Updated progression-free survival
analysis (reproduced with permission) [22]. EOC = epithelial ovarian cancer. PPC = primary peritoneal cancer. FTC = fallopian tube cancer.
C = Carboplatin. AUC = area under the curve. P = Paclitaxel. Bev = bevacizumab. CGIG = Gynecologic Cancer InterGroup. q3w = once every 3 weeks.
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log-rank) [23]. QoL scores assessed by the European
Organisation for Research and Treatment of Cancer QLQ-
C30 and QLQ-OV28 questionnaires suggested clinic-
ally small, but statistically significant deficits in global
QoL (p < 0.0001) following the addition of bevacizu-
mab to CP [29].
OCEANS
The OCEANS study is assessing the efficacy and safety
of CG with or without bevacizumab in patients with
platinum-sensitive recurrent EOC, FTC or PPC. A total
of 484 patients whose disease had recurred ≥ 6 months
after front-line platinum-containing chemotherapy were
randomized 1:1 to receive CG plus bevacizumab or CG
plus placebo. At the time of the final PFS analysis,median follow-up was 24 months, with 338 events [24].
The addition of bevacizumab to CG significantly increased
PFS, the primary endpoint, compared with placebo
(p < 0.0001) (Table 1). These findings were confirmed
by IRC assessment, which reported an increase in me-
dian PFS from 8.6 months to 12.3 months with the
addition of bevacizumab (HR 0.451, 95% CI: 0.351–0.580;
p < 0.0001) [24]. A statistically significant improvement
in ORR was also observed in the bevacizumab group
relative to placebo (Table 1), with a majority of partial
responses reported (61.2% bevacizumab vs. 48.3% pla-
cebo). The duration of response was also longer in
patients receiving bevacizumab than in those receiving
placebo (10.4 vs. 7.4 months, respectively; HR 0.534,
95% CI: 0.408–0.698). No difference in OS was ob-
served between the treatment groups at the third interim
Aravantinos and Pectasides Journal of Ovarian Research 2014, 7:57 Page 6 of 13
http://www.ovarianresearch.com/content/7/1/57analysis of the data after a median follow-up of 42 months
(Table 1) [25].
AURELIA
The AURELIA trial is investigating the combination of
bevacizumab and chemotherapy in platinum-resistant
recurrent ovarian cancer. A total of 361 patients with
ovarian cancer whose disease had progressed ≤ 6 months
after ≥ 4 cycles of platinum-based chemotherapy were
randomized to receive chemotherapy alone or in com-
bination with bevacizumab (pegylated liposomal doxo-
rubicin [PLD], n = 126; topotecan, n = 120; or paclitaxel,
n = 115) [26]. Median follow-up after 301 PFS events
was 13.5 months [26]. A statistically significant and
clinically meaningful improvement in PFS (p < 0.001),
the primary study endpoint, and in ORR (p = 0.001)
was observed in the bevacizumab plus chemotherapy
group compared with the chemotherapy alone group
(Table 1). No difference in OS was observed between
the treatment groups at the final data analysis [27].
More patients receiving bevacizumab plus chemother-
apy showed a ≥ 15% improvement in the QLQ-OV28
abdominal/gastrointestinal [GI] symptom subscale at
Week 8/9 compared with those receiving chemotherapy
alone (21.9% vs. 9.3%, respectively, 95% CI: 4.4–20.9;
p = 0.002) [30].
Bevacizumab is being evaluated in a number of on-
going, randomized, phase III trials in ovarian cancer.
The GOG-0241 study is comparing front-line CP with
or without bevacizumab versus oxaliplatin and cape-
citabine with or without bevacizumab in patients with
mucinous EOC or FTC [31]. GOG-0213 is enrolling
patients with platinum-sensitive recurrent EOC, PPC
or FTC who have undergone cytoreductive surgery to
receive CP with or without bevacizumab, followed by
bevacizumab and secondary cytoreductive surgery [32].
The AGO-OVAR 17 trial is evaluating the optimal treat-
ment duration of front-line bevacizumab in combin-
ation with CP (15 vs. 30 months) in EOC, FTC or PPC
[33]. GOG-0252 is examining bevacizumab combined
with intravenous or intraperitoneal chemotherapy in stage
II–IV ovarian cancer [34]. Finally, GOG-0262 is com-
paring the standard once every 3 weeks CP with dose-
dense weekly paclitaxel in combination with carboplatin
(Katsumata regimen) with or without concurrent and
consolidation bevacizumab in EOC, PPC or FTC [35].
Prior to enrolment in GOG-0262, each patient de-
cides whether their treatment will include concurrent
and maintenance bevacizumab based on discussion of
the risk to benefit ratio with their clinician. Safety re-
sults from the phase II OCTAVIA study examining front-
line bevacizumab plus weekly paclitaxel plus once every
3 weeks carboplatin, followed by single-agent bevacizu-
mab, are promising [36].Biomarker analyses
The potential prognostic and predictive value of VEGF-A
has been examined in studies of bevacizumab across mul-
tiple tumor types. In biomarker analyses of post-surgery
samples from the GOG-0218 study, a lack of correlation
was found between plasma VEGF-A levels and time since
surgery [37]. However, in an exploratory analysis of a
phase II study of bevacizumab and erlotinib in platinum-
resistant ovarian cancer, a prognostic association between
tumor VEGF-A expression and disease progression (PD)
was identified (p = 0.03); for every 100-unit increase in
the VEGF-A score, there was a 3.7-fold increase in
the odds of progression (95% CI: 1.1–16.6) [38]. High
baseline serum VEGF levels correlated with poor OS
(p = 0.01) in a phase II study of bevacizumab in patients
with chemotherapy-resistant ovarian cancer [39]. High
serum levels of platelet-derived growth factor (PDGF)-BB
and fibroblast growth factor 2 were of prognostic signifi-
cance in this study, but none of the markers predicted re-
sponse to bevacizumab. Further research is needed to
clarify the role of clinical and biologic factors in predicting
response to bevacizumab. Prognostic, but not predictive,
biomarker data will be collected in the MANGO-2 phase
IV trial [40] in patients with advanced ovarian cancer re-
ceiving front-line bevacizumab in combination with CP.
Safety of bevacizumab in advanced ovarian cancer
An overview of grade ≥ 3 adverse events (AEs) occurring
in the four phase III trials of bevacizumab identified in the
literature search is presented in Table 2. The type and fre-
quency of bevacizumab-related AEs was as expected, with
hypertension, thromboembolic events, proteinuria, bleed-
ing and GI events occurring at a higher incidence in the
bevacizumab-containing arms than in the control arms.
In the GOG-0218 study, grade ≥ 2 hypertension was sig-
nificantly more common in patients receiving bevacizu-
mab versus the control group (p < 0.001) but there were
no significant differences in the incidence of the other
treatment-emergent AEs. Fatal AEs were reported in 1.0%,
1.6% and 2.3% of patients in the control group, bevacizu-
mab initiation group and bevacizumab maintenance group,
respectively [21]. Grade ≥ 2 hypertension was reported
more frequently in the bevacizumab-containing arm of the
ICON7 study compared with the chemotherapy-alone arm
(18% vs. 2%, respectively). Five deaths related to treatment
or PD were reported on the ICON7 study: one in the
chemotherapy arm (0.1%) and four in the bevacizumab
arm (0.5%) [22].
Both the AURELIA and OCEANS trials have strict inclu-
sion criteria designed to minimize the risk of GI perfora-
tions, based on prior observations that GI perforation risk
was increased in patients with ovarian cancer recurrent
after multiple lines of therapy. An updated safety analysis
of the OCEANS study confirmed the findings at the time
Table 2 Grade ≥ 3 adverse events occurring in randomized phase III trials of bevacizumab in advanced ovarian cancer
Grade ≥ 3 AE, %
GOG-0218 [21] ICON7 [22] OCEANS [41] AURELIA [26]
CP + placebo CP + Bev CP + Bev→ Bev CP CP + Bev→ Bev CG + placebo CG + Bev CTx CTx + Bev
(n = 601) (n = 607) (n = 608) (n = 753) (n = 745) (n = 233) (n = 247) (n = 182) (n = 179)
Neutropenia 57.7a 63.3a 63.3a 15 17 – – – –
Pain 41.6b 41.5b 47.0b – – – – – –
Thrombocytopenia – – – 2 3 34 40 – –
Hypertension 7.2b 16.5b 22.9b <1 6 0.4 17.8 – –
VTE 5.8c 5.3c 6.7c 2 4 – – 4 3
Febrile neutropenia 3.5c 4.9c 4.3c 2 3 – – 1 1
Proteinuria 0.7 0.7 1.6 <1 1 0.9 9.7 – –
Bleeding (non-CNS) 0.8 1.3 2.1 <1 1 0.9 5.7 1 1
Wound healing complications 2.8c 3.6c 3.0c <1 1 – – – –
ATE 0.8c 0.7c 0.7c 1 3 – – 0 2
GI events 1.2b 2.8b 2.6b <1 1 0 0 – –
Epistaxis – – – – – 0.4 4.9 – –
Abscess/fistula – – – 1 1 0.4c 1.6c – –
RPLS 0 0.2c 0.2c 0 0 0 0.8c 0 1
CHF – – – <1 <1 – – 1 1
CNS bleeding 0 0 0.3c 0 <1 – – – –
AE = adverse event. ATE = arterial thromboembolic event. Bev = bevacizumab. C = carboplatin. CHF = congestive heart failure. CNS = central nervous system. CTx = chemotherapy. G = gemcitabine. GI = gastrointestinal.
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grade ≥3 proteinuria and hypertension reported in the bev-
acizumab arm relative to the placebo arm (Table 2) were
thought to be due to the longer treatment duration of bev-
acizumab. Bevacizumab-related GI perforations were mini-
mized in the AURELIA study due to the strict inclusion
criteria [26].
Emerging anti-angiogenic agents in ovarian cancer
A number of investigational anti-angiogenic agents are
currently in phase II/III development for the treatmentTable 3 Summary of efficacy data from phase II/III trials of eme
Study (n) Regimen
Matulonis et al. [42] Cediranib 45 mg/day
(n = 46)
Ledermann et al. [43] Cediranib 20 mg/day→ cedarinib
maintenance vs. placebo
(n = 456)
Du Bois et al. [44] Pazopanib 800 mg/day vs. placebo
(n = 940)
Campos et al. [45] Sunitinib 37.5 mg/day
(n = 35)
Biagi et al. [46] Sunitinib 50 mg/day (int.)
(n = 30)
Baumann et al. [47] Sunitinib 50 mg/day (int.) vs.
37.5 mg/day (cont.)
(n = 73)
Matei et al. [48] Sorafenib 400 mg b.i.d.
(n = 71)
Herzog et al. [49] Sorafenib 400 mg b.i.d. vs. placebo
(n = 249)
Ledermann et al. [50] Nintedanib 250 mg b.i.d. vs. placebo
(n = 83)
Du Bois et al. [51] Nintedanib 200 mg b.i.d. + CP vs.
nintedanib + placebo
(n = 1,366)
Coleman et al. [52] Aflibercept 6 mg/kg + D
(n = 46)
Gotlieb et al. [53] Aflibercept 4 mg/kg vs. placebo
(n = 55)
Colombo et al. [54] Aflibercept 4 mg/kg
(n = 16)
Karlan et al. [55] Trebananib 10 mg/kg + P vs.
trebananib 3 mg/kg + P vs. placebo + P
(n = 161)
Monk et al. [56] Trebananib 15 mg/kg + P vs. placebo + P
(n = 919)
b.i.d. = twice daily. cont = continuous. CR = complete response. D = docetaxel. in
PFS = progression-free survival. P = paclitaxel. PR = partial response.
aTime in days.
bTime in weeks.
CInterim data.of recurrent ovarian cancer. Table 3 summarizes avail-
able phase II/III efficacy data for these agents.
Trebananib
Trebananib (AMG 386) is an anti-angiopoietin peptide
that blocks the interaction of angiopoietin-1 and −2 with
the Tie2 receptor [55]. In a randomized, double-blind,
phase II trial, 161 patients with recurrent ovarian cancer
received weekly paclitaxel and were randomized 1:1:1
to receive trebananib (10 mg/kg or 3 mg/kg) or placebo
until PD, unacceptable toxicity or withdrawal of consent.rging anti-angiogenic agents in recurrent ovarian cancer
ORR
(CR + PR), %
Median PFS, months Median OS, months





11.4 vs. 9.4 20.3 vs. 17.6
– 17.9 vs. 12.3 Not reached
8.3 9.9b –
13.3 4.1 –
16.7 vs. 5.4 4.8 vs. 2.9 13.6 vs. 13.7
3.4 6-month PFS rate: 24% –
– 386 vs. 478a –
– 36-week PFS rate: –
16.3% vs. 5.0%
– 17.3 vs. 16.6 –
54 6.2 24.3
– 6.3 vs. 7.3b 12.9 vs. 16.0b
– 8.5b –
37 vs. 19 vs. 27 7.2 vs. 5.7 vs. 4.6 22.5 vs. 20.4 vs. 20.9
38 vs. 30 7.2 vs. 5.4 19.0c vs. 17.3c
t = intermittent. ORR = objective response rate. OS = overall survival.
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activity with greatest efficacy at the 10 mg/kg dose (Table 3)
[55]. Grade ≥ 3 AEs occurring more frequently in the
trebananib-containing arms than in the placebo arm were
hypokalemia, peripheral neuropathy and dyspnea. A num-
ber of randomized, double-blind, phase III trials of treba-
nanib are currently ongoing. TRINOVA-1 is investigating
the combination of paclitaxel plus trebananib or placebo in
recurrent partially platinum-sensitive or -resistant EOC,
PPC or FTC [56]. The investigators recently reported
that trebananib prolonged PFS from a median of 5.4 months
in the control arm to 7.2 months (HR 0.66; p < 0.001).
Trebananib was associated with more AE-related treat-
ment discontinuations and edema events while class-
specific anti-VEGF associated AEs were not increased. OS
data are still immature [56]. TRINOVA-2 is assessing the
combination of PLD with trebananib or placebo in the
same setting [57]. TRINOVA-3 is exploring the efficacy of
front-line CP plus trebananib or placebo in patients with
stage III–IV EOC, PPC or FTC [58].
Aflibercept
The novel fusion protein, aflibercept, binds and neutral-
izes all forms of VEGF-A and VEGF-B and inhibits PlGF
activation [59,60]. A phase II multicenter study combined
aflibercept with docetaxel every 3 weeks until PD or with-
drawal of consent in 46 patients with recurrent ovarian
cancer. A high ORR (25 patients, 54%) was achieved,
including 10 complete responders, 4 of whom had not
recurred at a median of 12 months (range: 5–22 months)
post-treatment [52]. Median PFS and OS compared favor-
ably with published data for other investigational agents in
this setting (Table 3). The most frequently reported grade
3/4 AEs were absolute neutrophil count (72%), fatigue
(50%), dyspnea (22%) and stomatitis (7%) [52].
Single-agent aflibercept has been investigated in two
phase II studies in patients with advanced chemotherapy-
resistant ovarian cancer and symptomatic malignant asci-
tes. In a single-arm, open-label study in 16 patients, the
repeat paracentesis response rate was 62.5% (95% CI:
35.4–84.8) and the median time to repeat paracentesis
was 76.0 days (95% CI: 64.0–178.0), with a median PFS of
59.5 days (95% CI: 41.0–83.0) (Table 3) [54]. Two patients
experienced grade 3 AEs (hypertension and weight loss in
one patient, intestinal perforation in the other patient); no
grade 4 events were reported. In a larger randomized,
double-blind, placebo-controlled study in 55 patients, afli-
bercept significantly prolonged the median time to repeat
paracentesis compared with placebo (55.1 vs. 23.3 days,
respectively, 95% CI: 10.6–53.1; p = 0.0019) [53], but there
was no significant difference in survival between the treat-
ment groups (Table 3). Grade 3/4 treatment-emergent
AEs included dyspnea (20% aflibercept vs. 8% placebo),
fatigue or asthenia (13% vs. 44%, respectively) and dehydration(10% vs. 12%, respectively). Aflibercept was associated with
a higher incidence of fatal GI events than placebo (10% vs.
4%, respectively) [53].
Nintedanib
The triple angiokinase inhibitor, nintedanib (BIBF 1120),
showed a promising PFS benefit in a randomized, placebo-
controlled phase II study in 83 women with recurrent
ovarian cancer who had responded to chemotherapy, but
who were at high risk of further early recurrence (Table 3)
[50]. All patients received nintedanib or placebo for 9 cycles
or until PD or patient withdrawal. A similar proportion of
patients in the nintedanib and placebo arms experienced
grade 3/4 AEs (34.9% vs. 27.5%, respectively, p = 0.49), but
nintedanib-treated patients had significantly more diar-
rhea, nausea and vomiting (p < 0.001 vs. placebo). A signifi-
cantly higher proportion of nintedanib-treated patients
experienced grade 3/4 hepatotoxicity compared with
placebo-treated patients (51.2% vs. 7.5%; p < 0.001). The
randomized, double-blind, phase III AGO-OVAR12 trial
investigated the efficacy of front-line nintedanib and CP
versus nintedanib and placebo in patients with advanced
ovarian cancer [51]. Median PFS was significantly longer in
the nintedanib plus CP group (17.3 months) than in the
nintedanib plus placebo group (16.6 months) (HR 0.84;
95% CI: 0.72–0.98; p = 0.0239). A planned phase II trial will
also investigate nintedanib in bevacizumab-resistant, recur-
rent, or persistent ovarian cancer [61].
Cediranib
The oral tyrosine kinase inhibitor, cediranib, which targets
VEGF receptor 1, 2 and 3, was active in an open-label
phase II trial in 46 patients with platinum-resistant or
platinum-sensitive recurrent EOC, PPC or FTC who re-
ceived treatment until PD, unacceptable toxicity or with-
drawal of consent (Table 3) [42]. Due to toxicities observed
in the first 11 patients, the dose of cediranib was reduced
from 45 mg/day to 30 mg/day. More than 20% of patients
experienced grade 3 AEs, including hypertension (46%),
fatigue (24%), and diarrhea (13%). Grade 4 AEs were
reported in 8.7% of patients. The ICON6 randomized,
double-blind, placebo-controlled phase III trial evalu-
ated the addition of cediranib (concurrent or concurrent
and maintenance) to platinum-based chemotherapy in
women with platinum-sensitive relapsed ovarian cancer.
Longer restricted mean PFS was reported in the cediranib
concurrent and maintenance arm compared with the pla-
cebo arm (11.4 vs. 9.4 months; HR 0.68; p = 0.0022) as
well as longer restricted mean OS (20.3 vs. 17.6 months;
HR 0.70; p = 0.049) [43]. The dose of cediranib was further
reduced in the ICON6 trial to 20 mg/day following prob-
lems with toxicity and compliance at the higher dose.
Stage I of the trial will assess safety, while stage II will
investigate PFS, OS, toxicity and QoL. Stage II will be
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Imatinib mesylate
Imatinib mesylate is a tyrosine kinase inhibitor that pre-
vents binding of PDGF to its receptor, PDGFR, and in-
hibits downstream signaling through Akt [62]. Preliminary
efficacy results revealed an ORR of 33% in a phase II study
of weekly paclitaxel plus intermittent imatinib in 12
women with recurrent ovarian cancer previously treated
with platinum or paclitaxel who had received ≤2 regimens
for recurrence [63]. Overall, four grade 3 AEs (diarrhea,
edema and two cases of neutropenia) were reported, but
there were no grade 4 toxicities.
Pazopanib
Pazopanib is a small molecule inhibitor that targets
VEGFR, PDGFR and c-kit tyrosine kinases [64]. Data
from a randomized, double-blind, phase III trial in 940
women with advanced ovarian cancer who had not
progressed after front-line chemotherapy showed a statis-
tically significant PFS benefit for patients receiving pazo-
panib versus placebo (HR 0.766, 95% CI: 0.64–0.91;
p = 0.0021) (Table 3) [44]. OS data are not yet mature.
Pazopanib treatment was associated with a higher inci-
dence of AEs and serious AEs than placebo (26% vs. 11%,
respectively). Three patients receiving pazopanib and one
patient receiving placebo experienced fatal serious AEs.
Sorafenib
The multikinase inhibitor, sorafenib, has broad activity
against tyrosine kinase receptors, including VEGFR and
PDGFR, as well as angiogenic factors [65]. Modest activ-
ity was shown with sorafenib in an open-label phase II
study in 71 women with ovarian cancer or PPC who re-
lapsed within 12 months of platinum-based chemother-
apy (Table 3) [48]. Significant grade 3/4 AEs included
rash (n = 7), hand-foot syndrome (n = 9), metabolic dis-
orders (n = 10), GI disorders (n = 3), cardiovascular dis-
orders (n = 2) and pulmonary disorders (n = 2). Safety
data from this trial preclude further investigation of so-
rafenib monotherapy in recurrent ovarian cancer. In a
randomized, double-blind, phase II trial of maintenance
sorafenib in 249 women with EOC or PPC in complete
remission after initial platinum-based chemotherapy,
PFS did not differ significantly between the sorafenib
and placebo arms (Table 3), although there was an im-
balance in censoring noted [49]. Dose reductions were
more common with sorafenib (67.5%) than placebo
(30.1%), and duration of treatment was also shorter in
the sorafenib arm (median 17.6 weeks vs. 51.9 weeks
with placebo). Similarly, the addition of sorafenib to CP
failed to improve 2-year PFS or OS rates in a random-
ized phase II trial as front-line treatment for stage III/IVovarian cancer following cytoreductive surgery, but tox-
icity was increased with the combination regimen [66].
A number of randomized phase II trials are assessing
combination regimens with sorafenib in patients with
recurrent ovarian cancer. Chekerov and colleagues are
assessing the efficacy of topotecan alone, or combined
with sorafenib, in platinum-resistant recurrent ovarian
cancer. Initial safety results from the first 12 patients
suggest that sorafenib plus topotecan is a feasible and
safe regimen worthy of continued phase II evaluation
[67]. A phase II trial of sorafenib in combination with
bevacizumab for advanced ovarian cancer is currently
recruiting patients [68].
Sunitinib
Sunitinib is another multikinase inhibitor that targets
VEGF, PDGF, stem cell factor receptor (KIT) and FMS-
like tyrosine kinase-3 (FTL3) [69]. Results of a phase II
study demonstrated the activity of single-agent sunitinib
in 35 women with recurrent and refractory ovarian can-
cer (Table 3) [45]. Hypertension and GI symptoms were
the most common toxicities. Modest activity was also
shown in a phase II trial in 30 patients with recurrent
platinum-sensitive ovarian cancer receiving sunitinib
intermittently at 50 mg/day for 4 out of 6 weeks [46].
However, the same level of activity was not reported in
patients requiring a reduction to 30 mg/day continuous
dosing. Fatigue, GI symptoms, hand-foot syndrome and
hypertension were the most frequently occurring AEs.
More recently, a phase II trial compared continuous and
intermittent dosing of sunitinib in 73 women with
platinum-resistant ovarian cancer, who had received ≤ 3
prior chemotherapy regimens, and concluded that the
intermittent schedule showed greatest activity and
should be further evaluated in this setting (Table 3) [47].
The type and incidence of AEs between the treatment
groups was similar, and included fatigue, cardiovascular,
GI and abdominal symptoms.
Conclusions
Bevacizumab has demonstrated significant efficacy bene-
fits in four randomized, double-blind, phase III studies in
combination with standard chemotherapy for advanced
ovarian cancer, both as front-line treatment and in patients
with recurrent disease. These findings were confirmed in a
meta-analysis of these four studies, which concluded that
the addition of bevacizumab to chemotherapy offers mean-
ingful improvement in PFS and ORR in ovarian cancer
treatment [70]. The safety profile of bevacizumab was as
expected in these studies, most AEs resolved over time,
and no new safety signals were reported. Ongoing research
has so far failed to identify predictive markers of re-
sponse to bevacizumab thus precluding the selection
of patients most likely to gain benefit. Promising efficacy
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anti-angiogenic agents including trebananib, nintedanib
and pazopanib, which are in phase III development for ad-
vanced ovarian cancer. Furthermore, several trials are
assessing the efficacy and safety of bevacizumab in com-
bination with novel targeted agents in this setting.
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